MAIA (MAIA Biotechnology) EPS (Basic): $-0.62 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAIA MAIA Biotechnology Inc MAIA
33 GF Score
Price $1.33
! 1 Warning Sign
View Full Analysis

What is MAIA Biotechnology EPS (Basic)?

MAIA Biotechnology MAIA -3.62% 33 EPS (Basic) is $-0.62 as of Jun. 2026. GuruFocus rates MAIA with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

MAIA Biotechnology's basic earnings per share (Basic EPS) for the three months ended in Jun. 2026 was $-0.13. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.62.

MAIA Biotechnology's EPS (Diluted) for the three months ended in Jun. 2026 was $-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.62.

MAIA Biotechnology's EPS without NRI for the three months ended in Jun. 2026 was $-0.13. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was -0.64.

During the past 3 years, the average EPS without NRI Growth Rate was 25.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, MAIA Biotechnology's highest 3-Year average EPS without NRI Growth Rate was 25.20% per year. The lowest was -33.80% per year. And the median was 2.20% per year.

MAIA Biotechnology  (AMEX:MAIA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

MAIA Biotechnology EPS (Basic) Related Terms

MAIA Biotechnology EPS (Basic) Historical Data

* Premium members only.

The historical data trend for MAIA Biotechnology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MAIA Biotechnology EPS (Basic) Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -1.18 -1.75 -1.49 -1.05 -0.70

MAIA Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.27 -0.08 -0.14 -0.13
MAIA
33GF Score
MAIA Biotechnology Inc MAIA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MAIA Biotechnology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

MAIA Biotechnology's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-22.396-0)/32.115
=-0.70

MAIA Biotechnology's Basic EPS for the quarter that ended in Jun. 2026 is calculated as

Basic EPS (Q: Jun. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.944-0)/60.794
=-0.13

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.62 mean?
MAIA Biotechnology (MAIA) has a EPS (Basic) of $-0.62 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on MAIA Biotechnology and its competitors.
Is MAIA Biotechnology's EPS (Basic) too high?
MAIA Biotechnology's current EPS (Basic) is $-0.62. Overall, MAIA Biotechnology has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MAIA Biotechnology's EPS (Basic) compare to GANX and PYPD?
MAIA Biotechnology's EPS (Basic) of $-0.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on MAIA Biotechnology and its competitors. MAIA Biotechnology's current EPS (Basic) is $-0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MAIA Biotechnology stock overvalued right now?
MAIA Biotechnology (MAIA) has a current EPS (Basic) of $-0.62. The current EPS (Basic) is $-0.62. MAIA Biotechnology's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For MAIA Biotechnology (MAIA), the current EPS (Basic) is $-0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MAIA Biotechnology Business Description

Address 444 West Lake Street, Suite 1700, Chicago, IL, USA, 60606
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
33GF Score

Get the complete analysis for MAIA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price